AstraZeneca PLC (AZN) Latest Company News

Jul 31, 2026, 08:00 UTC
AstraZeneca and Daiichi Sankyo's Datroway was approved in the European Union as monotherapy for first-line treatment of metastatic triple-negative breast cancer patients not eligible for immunotherapy.
Source:
- finanznachrichten.de
Jul 30, 2026, 09:00 UTC
AstraZeneca reversed its decision to remove Zoladex from the Australian Pharmaceutical Benefits Scheme and will now provide the drug free of charge to patients with no suitable alternative, with no end date.
Source:
- sbs.com.au
Jul 29, 2026, 19:00 UTC
AstraZeneca announces it will provide Zoladex (goserelin 3.6mg implant) to eligible women in Australia free of charge indefinitely, reversing a planned withdrawal from the PBS and private market.
Source:
- abc.net.au
Jul 29, 2026, 00:00 UTC
Fortrea Holdings Inc. appointed David Smith as Interim Chief Financial Officer and principal financial officer, effective July 27, 2026.
Jul 27, 2026, 20:50 UTC
European stocks closed flat on Monday, with the Stoxx 600 index at 644.52 points, as gains from easing US-Iran tensions and falling oil prices were offset by losses in technology stocks.
Source:
- sana.sy
Jul 27, 2026, 09:24 UTC
CSPC Innovation expects to turn a profit in the first half of 2026, achieving a high level of profitability.
Source:
- finance.sina.cn
- wap.eastmoney.com
Jul 27, 2026, 09:00 UTC
AstraZeneca announced an increased interim dividend of $1.06 per share for Q2 2026 and intends to raise the annual dividend to $3.30 per share for FY 2026.
Source:
- finanznachrichten.de
- rttnews.com
Jul 27, 2026, 07:01 UTC
AstraZeneca announced that its rare disease drug Ultomiris failed a late-stage trial in patients with a blood vessel complication following a stem cell transplant.
Source:
- reuters.com
Jul 24, 2026, 12:30 UTC
The CHMP of the European Medicines Agency recommended approval of Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for first-line treatment of unresectable or metastatic HER2-positive breast cancer in the EU.
Source:
- miragenews.com
Jul 24, 2026, 11:30 UTC
The CHMP of the EMA recommended approval of AstraZeneca's Trixeo Aerosphere for maintenance treatment of asthma in the EU.
Source:
- miragenews.com
Jul 14, 2026, 16:17 UTC
Hagens Berman opened an investigation into Ionis Pharmaceuticals for potential securities law violations after a trial failure caused a 23% stock drop.
Source:
Jul 9, 2026, 11:42 UTC
AstraZeneca and Ionis Pharmaceuticals launched eplontersen sodium injection (Wainua) in China on July 8, 2026.
Source:
- finance.sina.cn
Jul 4, 2026, 13:34 UTC
Hong Kong's Lok Ma Chau Loop Hong Kong-Shenzhen Innovation and Technology Park has attracted 90 technology companies to sign leases and move in as of end-May, with 10 being listed or leading innovation firms.
Source:
Jul 2, 2026, 01:00 UTC
Abbisko Therapeutics entered a strategic collaboration agreement with AstraZeneca to jointly advance clinical development of a novel IO-TKI combination therapy for NSCLC.
Source:
- prnewswire.com
- benzinga.com
Jun 29, 2026, 23:00 UTC
Texas Attorney General's Office announced a $34 million settlement with AstraZeneca Pharmaceuticals LP over allegations of an illegal kickback scheme that influenced Medicaid-covered prescriptions.
Source:
Jun 29, 2026, 14:55 UTC
AstraZeneca's Datroway received a positive CHMP opinion, moving closer to a first-line EU approval for triple-negative breast cancer.
Source:
- zacks.com
- zacks.com
Jun 29, 2026, 14:55 UTC
AstraZeneca's Enhertu received EU approval for HER2-positive solid tumors, its sixth EU indication.
Source:
- zacks.com
- zacks.com
Jun 24, 2026, 13:00 UTC
AstraZeneca and YMCA of the USA announced a five-year partnership to strengthen cancer education and support programs.
Source:
- businesswire.com
Jun 23, 2026, 05:30 UTC
Korea Health Industry Development Institute held partnering sessions for 13 Korean biotech companies with AstraZeneca under Project NOVA at the BIO International Convention in San Diego.
Source:
- koreaherald.com
Jun 16, 2026, 17:56 UTC
The FDA accepted AstraZeneca's filing for expanded use of Ultomiris to treat IgA nephropathy, granting priority review.
Source:
- zacks.com
Jun 12, 2026, 22:44 UTC
The US FDA approved AstraZeneca's TRUQAP (capivasertib) combination as a targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer.
Source:
- businesswire.com
- zacks.com
Jun 9, 2026, 13:35 UTC
AstraZeneca reported encouraging mid-stage trial results for its experimental weight-loss pill elecoglipron, showing 11.8% weight loss after 36 weeks.
Source:
Jun 5, 2026, 00:00 UTC
AbCellera Biologics Inc. appointed Victor Sandor as a Director, effective June 1, 2026.

← PreviousPage 2

AZN

AstraZeneca and Daiichi Sankyo's Datroway was approved in the European Union as monotherapy for first-line treatment of metastatic triple-negative breast cancer patients not eligible for immunotherapy.

AstraZeneca reversed its decision to remove Zoladex from the Australian Pharmaceutical Benefits Scheme and will now provide the drug free of charge to patients with no suitable alternative, with no end date.

AstraZeneca announces it will provide Zoladex (goserelin 3.6mg implant) to eligible women in Australia free of charge indefinitely, reversing a planned withdrawal from the PBS and private market.

Fortrea Holdings Inc. appointed David Smith as Interim Chief Financial Officer and principal financial officer, effective July 27, 2026.

European stocks closed flat on Monday, with the Stoxx 600 index at 644.52 points, as gains from easing US-Iran tensions and falling oil prices were offset by losses in technology stocks.

CSPC Innovation expects to turn a profit in the first half of 2026, achieving a high level of profitability.

AstraZeneca announced an increased interim dividend of $1.06 per share for Q2 2026 and intends to raise the annual dividend to $3.30 per share for FY 2026.

AstraZeneca announced that its rare disease drug Ultomiris failed a late-stage trial in patients with a blood vessel complication following a stem cell transplant.

The CHMP of the European Medicines Agency recommended approval of Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for first-line treatment of unresectable or metastatic HER2-positive breast cancer in the EU.

The CHMP of the EMA recommended approval of AstraZeneca's Trixeo Aerosphere for maintenance treatment of asthma in the EU.

Hagens Berman opened an investigation into Ionis Pharmaceuticals for potential securities law violations after a trial failure caused a 23% stock drop.

AstraZeneca and Ionis Pharmaceuticals launched eplontersen sodium injection (Wainua) in China on July 8, 2026.

Hong Kong's Lok Ma Chau Loop Hong Kong-Shenzhen Innovation and Technology Park has attracted 90 technology companies to sign leases and move in as of end-May, with 10 being listed or leading innovation firms.

Abbisko Therapeutics entered a strategic collaboration agreement with AstraZeneca to jointly advance clinical development of a novel IO-TKI combination therapy for NSCLC.

Texas Attorney General's Office announced a $34 million settlement with AstraZeneca Pharmaceuticals LP over allegations of an illegal kickback scheme that influenced Medicaid-covered prescriptions.

AstraZeneca's Datroway received a positive CHMP opinion, moving closer to a first-line EU approval for triple-negative breast cancer.

AstraZeneca's Enhertu received EU approval for HER2-positive solid tumors, its sixth EU indication.

AstraZeneca and YMCA of the USA announced a five-year partnership to strengthen cancer education and support programs.

Korea Health Industry Development Institute held partnering sessions for 13 Korean biotech companies with AstraZeneca under Project NOVA at the BIO International Convention in San Diego.

The FDA accepted AstraZeneca's filing for expanded use of Ultomiris to treat IgA nephropathy, granting priority review.

The US FDA approved AstraZeneca's TRUQAP (capivasertib) combination as a targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer.

AstraZeneca reported encouraging mid-stage trial results for its experimental weight-loss pill elecoglipron, showing 11.8% weight loss after 36 weeks.

AbCellera Biologics Inc. appointed Victor Sandor as a Director, effective June 1, 2026.